These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18020898)

  • 1. Cardiac biomarkers: myths, facts and future horizons.
    Dotsenko O; Chackathayil J; Lip GY
    Expert Rev Mol Diagn; 2007 Nov; 7(6):693-7. PubMed ID: 18020898
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin.
    May A; Wang TJ
    Expert Rev Mol Diagn; 2007 Nov; 7(6):793-804. PubMed ID: 18020909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for cardiovascular disease: challenges and future directions.
    May A; Wang TJ
    Trends Mol Med; 2008 Jun; 14(6):261-7. PubMed ID: 18487087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel biomedical risk markers for cardiovascular disease.
    Magliano DJ; Liew D; Ashton EL; Sundararajan V; McNeil JJ
    J Cardiovasc Risk; 2003 Feb; 10(1):41-55. PubMed ID: 12569236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to identify the asymptomatic high-risk patient?
    Schuijf JD; Achenbach S; Zoghbi WA; Boersma E; Raggi P; Weber M; Nagel E; Narula J; Wackers FJ; Poldermans D; Bax JJ
    Curr Probl Cardiol; 2009 Nov; 34(11):539-77. PubMed ID: 19804855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New risk markers may change the HeartScore risk classification significantly in one-fifth of the population.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    J Hum Hypertens; 2009 Feb; 23(2):105-12. PubMed ID: 18784734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing and assessing cardiovascular biomarkers.
    Dadu RT; Nambi V; Ballantyne CM
    Transl Res; 2012 Apr; 159(4):265-76. PubMed ID: 22424430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple biomarkers and cardiovascular risk.
    Austin MJ; Heneghan MA
    N Engl J Med; 2008 Aug; 359(7):760-1; author reply 761. PubMed ID: 18711791
    [No Abstract]   [Full Text] [Related]  

  • 9. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases.
    Rubattu S; Sciarretta S; Valenti V; Stanzione R; Volpe M
    Am J Hypertens; 2008 Jul; 21(7):733-41. PubMed ID: 18464748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in acute cardiovascular disease.
    Howie-Esquivel J; White M
    J Cardiovasc Nurs; 2008; 23(2):124-31. PubMed ID: 18382255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in acute cardiac disease: the present and the future.
    Jaffe AS; Babuin L; Apple FS
    J Am Coll Cardiol; 2006 Jul; 48(1):1-11. PubMed ID: 16814641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
    Goei D; Hoeks SE; Boersma E; Winkel TA; Dunkelgrun M; Flu WJ; Schouten O; Bax JJ; Poldermans D
    Coron Artery Dis; 2009 May; 20(3):219-24. PubMed ID: 19322079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular biomarkers: the state of the art in 2006.
    Jaffe AS
    Clin Chim Acta; 2007 May; 381(1):9-13. PubMed ID: 17368598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
    Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
    J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of biomarkers for risk stratification in the prevention of cardiovascular diseases].
    Sinning C; Keller T; Blankenberg S
    Dtsch Med Wochenschr; 2009 Oct; 134(40):2019-22. PubMed ID: 19777420
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of cardiac biomarkers in end-stage renal disease.
    Wang AY; Lai KN
    J Am Soc Nephrol; 2008 Sep; 19(9):1643-52. PubMed ID: 18322158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does C-reactive protein represent an oxidative stress marker in cardiovascular disease?
    Korantzopoulos P; Papaioannides D; Galaris D; Kokkoris S
    Int J Clin Pract; 2003 Apr; 57(3):252. PubMed ID: 12723737
    [No Abstract]   [Full Text] [Related]  

  • 18. CRP as a marker for cardiovascular risk.
    Savill P
    Practitioner; 2008 Dec; 252(1713):4. PubMed ID: 19192697
    [No Abstract]   [Full Text] [Related]  

  • 19. Hot and bothered: C-reactive protein, inflammation and atherosclerosis.
    Wierzbicki AS
    Int J Clin Pract; 2009 Nov; 63(11):1550-3. PubMed ID: 19832810
    [No Abstract]   [Full Text] [Related]  

  • 20. Biochemical risk markers: a novel area for better prediction of renal risk?
    Stuveling EM; Bakker SJ; Hillege HL; de Jong PE; Gans RO; de Zeeuw D
    Nephrol Dial Transplant; 2005 Mar; 20(3):497-508. PubMed ID: 15735241
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.